Respiratory Distress Syndrome Newborn
📧 Sign up to get email alerts when something new happens for Respiratory Distress Syndrome Newborn.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2006-06-08EMA Application withdrawn: Surfaxin (sinapultide;Dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol;palmitic acid) — Pharm Research Associates (UK) Limited
EMA withdrew the application for Surfaxin (sinapultide and lipid components) for Respiratory Distress Syndrome in newborns.